Tech Center 1600 • Art Units: 1635 1637 1674
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18786394 | RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES | Non-Final OA | The Regents of the University of California |
| 18014700 | COMPOSITIONS AND METHODS FOR INCREASING HOMOLOGY-DIRECTED REPAIR | Non-Final OA | The Regents of the University of California |
| 18192108 | DOUBLE-STRANDED RNA THAT INHIBITS PRODUCTION OF HEPATITIS B VIRUS PROTEIN AND PHARMACEUTICAL COMPOSITION | Non-Final OA | FUJIFILM Corporation |
| 17936715 | Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 19094456 | UTILIZATION OF GENE TARGETING ANTIBODY FUSION PROTEINS TO PERFORM IN VIVO THERAPEUTIC GENE EDITING | Non-Final OA | Baylor College of Medicine |
| 17637427 | TARGETING SLC38A2 IN PANCREATIC CANCER | Final Rejection | New York University |
| 17619232 | ANTAGONISTS OF CAMKII-DELTA 9 AND USES THEREOF | Final Rejection | PEKING UNIVERSITY |
| 17943442 | METHOD OF TREATING CANCER AND METHOD OF SENSITIZING CANCER CELLS TO THE ACTION OF CHEMOTHERAPEUTIC AGENTS VIA GROWTH HORMONE RECEPTOR ANTAGONISTS OR KNOCK DOWN | Final Rejection | Ohio University |
| 17998128 | SYSTEMS AND METHODS FOR TREATING LEVODOPA DYSKINESIA, ENHANCING MOTOR BENEFIT, AND DELAYING DISEASE PROGRESSION | Non-Final OA | Board of Trustees of Michigan State University |
| 17126439 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | Final Rejection | Roche Diagnostics Operations, Inc. |
| 17640647 | CHIMERIC COMPLEX AND THERAPEUTIC USES THEREOF | Non-Final OA | CONSIGLIO NAZIONALE DELLE RICERCHE |
| 18145234 | MAMMALIAN CELLS FOR PRODUCING A SECRETED PROTEIN | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 17384993 | MICRO-RNA-155 ENHANCES THE EFFICACY OF DENDRITIC CELL VACCINE FOR CANCER | Final Rejection | University of South Carolina |
| 17922365 | COMPOSITIONS COMPRISING EXOGENOUS HOMOLOGOUS DNA AND USES THEREOF | Non-Final OA | SUPERBREWED FOOD, INC. |
| 17982819 | CHIRALLY-ENRICHED DOUBLE-STRANDED RNA AGENTS | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 17697044 | GENOMIC SAFE HARBORS FOR TRANSGENE INTEGRATION | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17416108 | MODULATORS OF HSD17B13 EXPRESSION | Final Rejection | Ionis Pharmaceuticals, Inc. |
| 16948435 | Compositions for Modulating C9ORF72 Expression | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 16482844 | RNA CANCER VACCINES | Final Rejection | ModernaTX, Inc. |
| 17315987 | METHODS FOR GENERATING MACROPHAGES WITH ENHANCED CANCER PHAGOCYTOSIS | Non-Final OA | Georgia State University Research Foundation, Inc. |
| 17920250 | NUCLEIC ACID THAT INTERACTS WITH A RECEPTOR FOR ENDOCRINE DISRUPTING CHEMICALS AND USE THEREOF | Non-Final OA | UNIVERSITY PUBLIC CORPORATION OSAKA |
| 18194740 | ANTI-CHYMASE APTAMER AND USE FOR SAME | Non-Final OA | RIBOMIC INC. |
| 18074268 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Non-Final OA | Arrowhead Pharmaceuticals, Inc. |
| 18012867 | ARTIFICIAL RNAS FOR MODULATING RNA FRAGMENTS | Non-Final OA | UNIVERSITAT POMPEU FABRA |
| 17961097 | GENE CONSTRUCTS FOR SILENCING ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND USES THEREOF | Non-Final OA | uniQure IP B.V. |
| 17751934 | RNAI INDUCED HUNTINGTIN GENE SUPPRESSION | Final Rejection | Uniqure IP B.V. |
| 17623045 | NOVEL ADP-RIBOSYL CYCLASE AND INHIBITOR THEREOF | Non-Final OA | DNT Co., Ltd. |
| 17256092 | ARTIFICIAL NUCLEIC ACIDS FOR RNA EDITING | Final Rejection | Eberhard-Karls-Universität-Tübingen |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy